Overview of CRISPR and ERS Genomics.

2. Emmanuelle Charpentier
Founder: ERS Genomics
Winner: Nobel Prize
It was clear the scientific
community was waiting for…
a tool that will simplify the
genetics of their organisms
of choice…the spectrum of
applications, is quite incredible

3. The CRISPR/Cas9 patents are jointly owned
The Patent owners
are referred to as
“CVC”
While patents are jointly
owned, ERS operates
independently
and provides legal
access to the CVC
portfolio-no other
license from any CVC
member is required
Patent owners Exclusive licensees
CVC
Patents
E. Charpentier
The Regents of the
University of California
University of Vienna
ERS Genomics
CRISPR Therapeutics
(human gene & cell therapy)
(all fields except human gene & cell therapy)

4. Granted patents
Patent applications
World Patent Status
80+
countries
100+
Granted patents
Including over 1400 claims
in 52 US patents

5. You Will Always Need a License From ERS Genomics
A license from ERS covers usage of CRISPR/Cas9 in all cells. However, you may need other licenses.
If you want to use
CRISPR/Cas9 you start with
a foundational license from
ERS Genomics.
Depending on your goals you
may need an additional
license from company B (i.e.
The Broad).
Depending on your goals you
may need an additional
license from Company C
(other).
ERS
B
C

6. Our CRISPR patent portfolios cover:
Compositions & methods of
using Cas9 with dual or single
guide RNA and delivery formats
of these compositions in a cell
Use of CRISPR/Cas9
complex to cleave DNA
Using mutated Cas9, such
as dCas9 or nCas9, to:
• Nick DNA
• Bring an effector domain to a
specified DNA sequence, such
as for CRISPRi and CRISPRa
• Base editing
1(a)
1(b)
Foundational Method Patent Example: US 10,227,611
Foundational Composition Patent Example: US 10,407,697
1(a)
1(b)

7. Synthetic biology and
materials - enzymes,
biofuels, chemicals,
food, services
Discovery, validation, &
screening of novel drugs and
drug targets. Cell line & animal
model generation including iPSC
& stem cells.
Selling research tools, kits,
reagents, cell lines & animal
models for laboratory
research
Services including GMP
production of healthcare
products
Internal R&D Commercialization CRO, CMO & CDMO
Manufacturing of therapeutics
such as monoclonal
antibodies & proteins
Bioproduction
Personalized medicine products
and companion diagnostics
Clinical diagnostics
Disease treatment & prevention
Companion animals
& livestock
Industrial production
ERS Grants Licenses in the Following Fields:
Modification of
agriculture plants
Modification of human
cells in-vivo
Modification of human
cells in-vitro for
therapeutic applications
Outside our
jurisdiction:

8. Financial terms depend on
several factors:
Field
Territory
Company Size (FTEs)
Internal R&D
Commercial
applications
Bioproduction Animals
Worldwide Europe
North
America
Asia/Pacific
1 - 49 50 - 499 500 - 4999 5000 and over
Internal R&D use only:
Commercial Applications
(includes internal R&D use):
Bioproduction (add on)
Upfront Fee
Annual Maintenance Fee
(No reach through to Tx products)
Upfront Fee
Annual Minimum
Royalty
Royalty on Net Sales
Increased Upfront Fee
Annual per product
manufactured maintenance fee
License Structures

9. Internal Research CRO’s/CMOs Tools/Reagents Industrial Bio.
Some of Our Licensees…

10. Eric Rhodes
CEO
ERS Genomics
US mobile: +1 530 363 6148
eric.rhodes@ersgenomics.com
Jon Kratochvil
VP of Business
Development and Licensing
ERS Genomics
US mobile: +1 314 322 6170
jon.kratochvil@ersgenomics.com
Contact us
Paul Carter
Director Intellectual Property and
Corporate Development
ERS Genomics
US mobile: +1-919-457-8510
paul.carter@ersgenomics.com

11. Field
• Internal Research Only
• Cumulative investment under $5M
Propose Simplified Terms for US Academic Institutions *
University Startup
Annual Fee: $15,000
University Activities
• One time signature fee: $25,000
• Royalty: 8%
Field
• Licensing Cells & Cell Lines for
research use
• Licensing mice and other animal
models for research use
• Providing gene editing services
University Incubator
Annual Fee: $50,000
Field
• Internal Research Only
• Maximum 5 startups
• Cumulative investment under $5M
each
* Terms valid through June 30, 2023